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ABSTRACT  
 
    
BACKGROUND: The latest French good practice recommendations (GPRs) for the screening, prevention, and treatment of alcohol misuse were 
recently published in partnership with the European Federation of Addiction Societies (EUFAS). This article aims to synthesize the GPRs focused on 
the pharmacotherapy of alcohol dependence. 
 
METHODS: A four-member European steering committee defined the questions that were addressed to an 18-member multi-professional working 
group (WG). The WG developed the GPRs based on a systematic, hierarchical and structured literature search and submitted the document to two 
review processes involving 37 French members from multiple disciplines and 5 non-French EUFAS members. The final GPRs were graded A, B, or C, 
or expert consensus (EC) using a reference recommendation grading system.  
 
RESULTS:  
- The treatment of alcohol dependence consists of either 1) alcohol detoxification / abstinence maintenance programs or 2) drinking reduction 
programs.  
- The therapeutic objective is the result of a decision made jointly by the physician and the patient. 
- Benzodiazepines (BZDs) are the first-line medication for detoxification (GRADE A).  
- BZD dosing should be guided by regular clinical monitoring (GRADE B).  
- Residential detoxification is more appropriate for patients with a history of seizures, delirium tremens, unstable psychiatric comorbidity, or 
another associated substance use disorder (GRADE B).  
- BZDs are only justified beyond a one-week period in the case of persistent withdrawal symptoms, withdrawal events or associated BZD 
dependence (GRADE B).  
- BZDs should not be continued for more than four weeks (GRADE C).  
- The dosing and duration of thiamine (vitamin B1) during detoxification should be adapted to nutritional status (EC).  
- Medications for relapse prevention should be automatically associated with adapted psychosocial support (GRADE A).  
- Acamprosate and naltrexone are the first-line options for relapse prevention (GRADE A).  
- Disulfiram can be proposed as second-line treatment in patients who are correctly informed and adequately supervised (EC). 
- Medications for reducing alcohol consumption are only indicated in dependent individuals (EC).  
- Nalmefene is indicated as a first-line treatment for reducing alcohol consumption (GRADE A).  
- The second-line prescription of baclofen, up to 300 mg/d, to prevent relapse or reduce drinking should be carried out according to the “temporary 
recommendation for use” (TRU) issued by the French Health Agency (EC). 
- Abstinence is recommended throughout pregnancy (EC). 
- If medically‐assisted withdrawal is necessary during pregnancy, BZD use is recommended (GRADE B). 
- No medication other than those for alcohol withdrawal should be initiated in pregnant or breastfeeding women (EC). 
- In a stabilized pregnant patient taking medication to support abstinence, the continuation of the drug should be considered on a case‐by‐case 
basis, weighing the benefit/risk ratio. Only disulfiram should be always stopped, given the unknown risks of the antabuse effect on the fetus (EC). 
- First‐line treatments to help maintain abstinence or reduce drinking are off-label for people under 18 years of age and should thus be considered 
on a case-by-case basis after the repeated failure of psychosocial measures alone (EC). 
- Short-half-life BZDs should be preferred for the detoxification of elderly patients (GRADE B). 
- The initial doses of BZDs should be reduced by 30 to 50% in elderly patients (EC). 
- In patients with chronic alcohol-related physical disorders, the goal of abstinence is recommended (EC) 
- Any antidepressant or anxiolytic medication should be introduced after a psychiatric reassessment after 2-4 weeks of alcohol abstinence or low-
risk use (GRADE B). 
- A smoking cessation program should be offered to any smokers involved in an alcohol treatment program (GRADE B). 
 
DISCLAIMER: The French guidelines are based on the both the available evidence and national aspects of clinical practice. They do not constitute 
inflexible treatment recommendations.  
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1.  INTRODUCTION  
Alcohol dependence is usually defined as the most severe stage of alcohol use disorders (AUDs)(1), 
and it defines the clinical boundary beyond which the use of pharmacological treatments is officially 
indicated (2). Recently, new treatment strategies and medications have been developed to treat 
alcohol dependence. Drinking reduction programs have been increasingly proposed as an alternative 
of detoxification and subsequent abstinence maintenance among patients with alcohol dependence. 
Such programs aim to target the patients for whom the classical abstinence-based treatment 
strategies are unappealing or unattainable (3) and thus to reduce the important treatment gap 
observed among patients with AUDs (4). These new concepts have been developed worldwide, and a 
new medication, nalmefene, has been recently introduced in Europe as a pharmacological support for 
drinking reduction programs (5). Because practices are evolving, national guidelines must frame and 
integrate the new treatment concepts, taking into account both the international evidence and the 
local care system and medical culture.  
In France, two former national guideline documents date back to 1999 and 2001 (6,7). They essentially 
emphasized the classic alcohol dependence treatment program based on assisted detoxification and 
abstinence maintenance (8). Moreover, the French addiction care system has evolved considerably 
since 2001, and the birth of addiction medicine as a holistic and individualized discipline has led to the 
implementation of specific multiaddiction treatment facilities that now integrate the French territory 
and aim to provide a more standardized care (9). More importantly, a recent development in the field 
specific to France has been the spread and the official regulation of the off-label use of high-dose 
baclofen for alcohol dependence, abstinence maintenance and drinking reduction (10).  
For these reasons, it was necessary to develop new, updated, and methodologically rigorous good 
practice recommendations (GPRs) for French clinicians that encompass recent national and 
international developments pertaining to the treatment of alcohol misuse. The purpose of these new 
GPRs was to integrate the features of the French health system and local specificities and to meet the 
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international requirements for high quality standards, including full ethical and methodological 
transparency and international scientific peer-review. Therefore, the Société Française d’Alcoologie 
(SFA), i.e., the French Alcohol Society, appealed to the European Federation of Addiction Societies 
(EUFAS) to support the development of new French guidelines. This support consisted of 1) 
participating in the entire drafting process of the GPRs as external observers and transparency 
advisors and 2) having the GPR document peer-reviewed by non-French European members of the 
EUFAS.  
The final GPRs were published online in French and in English and made accessible for free on the SFA 
Website (11,12). Overall, the GPRs are not restricted to alcohol dependence but embrace the much 
wider spectrum of alcohol misuse. This choice was made to emphasize the key role of primary care 
settings in the screening, detection, and treatment of any stage of alcohol misuse, including alcohol 
dependence (13). The aim of this article is to provide a synthesis of the French GPRs with a narrower 
focus on pharmacotherapy. As previously mentioned, alcohol dependence is the only stage of alcohol 
misuse in which pharmacotherapy is indicated. Therefore, only a portion of the French GPRs - i.e., the 
recommendations related to the therapeutic aspects of alcohol dependence and the specific 
management of medications in that context - is described herein.  
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2.  METHODS 
The committees and groups involved in the GPR-writing process were selected according to the 
methodological guidelines of the Haute Autorité de Santé (HAS), i.e., the French National Authority for 
Health (14). The HAS is an official French regulatory institution that aims to “bring together under a 
single roof a number of activities designed to improve the quality of patient care and to guarantee 
equity within the health care system” (15).  
A four-member steering committee was created in July 2013 (see a list of the participants in the 
acknowledgment section). The steering committee issued a list of 19 questions related to alcohol 
misuse. The steering committee then gathered an 18-member multidisciplinary and multiprofessional 
working group (WG). The WG performed an initial systematic review of the literature with the aim of 
providing recommendations regarding the 19 questions issued by the steering committee. Based on 
the literature review performed by the WG and the subsequent expert discussion among its members, 
the WG drafted the first version of the GPR document and graded each recommendation using the 
HAS grading grid (see Table 1) (14).  
- INSERT TABLE 1 HERE - 
The initial draft of the GPRs was submitted to a first peer-review group comprising 37 French general 
practitioners, addiction specialists, addiction researchers, nurses, midwifes, and members of patient 
associations. After the first round of peer review, the WG revised the recommendation document. The 
revised draft was then submitted to a second peer-review group comprised of 5 non-French members 
of the EUFAS. The final version was published online on the SFA’s website in both French and English 
(11,12). In the present article, we selected the recommendations related to the management of 
pharmacotherapy regarding AUDs. From the 19 initial questions about the GPRs, we selected the 
recommendations referring to 6 questions pertaining to medication prescription and treatment 
objectives (See Table 2).   
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- INSERT TABLE 2 HERE - 
 3.  RESULTS 
3.1 What are the objectives of the therapeutic intervention? 
The short version of the recommendations issued in response to this question is listed in Table 3.  
It has been stated that the therapeutic interventions for patients with alcohol dependence should 
primarily aim to improve the subject’s quality of life (EC). In practice, this implies reducing alcohol-
induced harms, i.e., those that affect the subject’s physical and mental health, interpersonal, social 
and professional adaptation, or legal situation. Such changes, however, require the subject to 
abandon harmful drinking patterns, which implies a protracted modification of alcohol use with the 
goal of either abstinence or a significant reduction in consumption (16,17). Consequently, the GPRs 
considered that therapeutic interventions for alcohol misuse, including alcohol dependence, should 
aim for abstinence or moderation (EC).  
- INSERT TABLE 3 HERE - 
Subjects with severe alcohol dependence, the misuse of multiple associated substances or severe 
psychiatric comorbidities are less likely to return to stable, low-risk alcohol use than are subjects who 
do not exhibit such features (18–20). Furthermore, the alcohol use outcome is substantially improved 
when the treatment goal is based on the informed decision of the service user (21,22). Such patient 
information also corresponds to current ethical requirements regarding the patient-physician 
relationship (23). Consequently, the objectives of therapeutic intervention for subjects with alcohol 
dependence should first rely on the informed decision of the service user (GRADE B).  
The severity of the alcohol dependence should also be taken into consideration. It has thus been 
recommended in the GPRs that abstinence should be the goal for subjects with severe alcohol 
dependence and/or dependence with significant psychiatric or physical comorbidity (EC). If the service 
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user is unable or unwilling to reach a goal of abstinence, a drinking reduction program aimed at harm 
reduction can be implemented, although the patient should be regularly encouraged to abstain (EC). 
For subjects with mild dependence, no significant comorbidities and good social support, a moderate 
level of drinking is a suitable goal unless the patient prefers abstinence (EC).  
In any case, any significant reduction in the average alcohol use, such as the proportion of heavy 
drinking, should be encouraged (GRADE A) because such reductions help reduce the overall risks and 
harms induced by alcohol.   
 
3.2 How should intervention be planned?  
Therapeutic interventions should be planned according to the consumption goal (i.e., abstinence or 
moderation). However, consumption goals may fluctuate from one period to another and between a 
goal of reducing alcohol use or abstaining and can vary either way. The motivation to change can be 
volatile.  
Regarding the abstinence goal, the therapeutic intervention can usually be separated into two phases: 
1) assisted alcohol withdrawal and 2) abstinence maintenance (or relapse prevention). These two 
phases should be distinguished, notably because they have different monitoring and therapeutic 
purposes and may require specific pharmacotherapy.  
For patients seeking moderation rather than abstinence, an assisted alcohol withdrawal period is not 
necessarily warranted. In this case, there is no clear distinction between the moderation period and the 
relapse prevention period because the two goals are generally combined (EC).  
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3.3 How should treatment with a goal of detoxification be conducted? 
Alcohol withdrawal consists of the immediate cessation of alcohol consumption. Alcohol withdrawal 
can be accidental, imposed by circumstances, or planned with a therapeutic aim. In patients with 
alcohol dependence, alcohol withdrawal may trigger an alcohol withdrawal syndrome (AWS) starting a 
few hours after the last alcohol intake and continuing for a few days. AWS can consist of numerous 
types of symptoms to varying degrees (24): 1) subjective disorders, i.e., anxiety, agitation, irritability, 
insomnia, and nightmares; 2) gastrointestinal disorders, i.e., anorexia, nausea, vomiting, and diarrhea; 
and 3) autonomic disorders, i.e., sweat, tremor, tachycardia, and hypertension. Complications of AWS 
include delirium, hallucinations, or seizures. The main risk factors for AWS complications include a 
high level of daily drinking, previous episodes of AWS, associated substance use disorders, and 
associated physical comorbidities (25). The intensity of AWS can vary. Approximately 95% of alcohol 
withdrawal situations are free of severe complications (26). However, complications can be serious 
and sometimes even life-threatening (24). AWS thus requires specific prevention, intervention and 
supervision efforts.  
Detoxification is defined as the medical procedure for rapidly and safely achieving an alcohol-free 
state in a subject with alcohol dependence. The recommendations issued in the GPR document 
concerning the overall management of alcohol detoxification can be viewed in Table 4. Alcohol 
detoxification can take place on an outpatient or residential basis. Residential detoxification is safer 
(24), whereas outpatient detoxification is less expensive (27). Outpatient detoxification is not 
recommended in patients with communication difficulties, a history of seizures, unstable psychiatric 
comorbidities or high-dose polydrug use, especially daily, historical or high-dose benzodiazepine (BZD) 
addiction (EC). Residential treatment should also be recommended on a case-by-case basis 
considering specific circumstances, such as the extent of the withdrawal syndrome, the failure of 
repeated outpatient detoxification attempts, severe or unstable comorbidity, age-related frailty, 
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pressing demands from the subject’s family, limited social support, a precarious social situation, or 
pregnancy (EC). In other situations, outpatient detoxification is preferable (EC).  
- INSERT TABLE 4 HERE - 
Alcohol detoxification may require preventive or therapeutic medications for AWS. BZDs have 
demonstrated good efficacy for preventing and treating AWS symptoms and complications (28) and 
have been the quasi-ubiquitous treatment for AWS prevention in France since the release of the 
French guidelines for the management of alcohol detoxification (7). Consequently, BZDs are the 
recommended medication for AWS (GRADE A). However, because AWS occurs in only a little more 
than half of alcohol-dependent patients (29), medications are not necessary for every patient (GRADE 
C). The symptom-adjusted prescription of BZDs is both safe and more strategy for the patient (30) and 
should be prioritized, although it is more easily applicable in residential settings, where the patient can 
be assessed several times a day (GRADE C). A symptom-adjusted treatment strategy may be supported 
by withdrawal symptom evaluation scales, such as the Clinical Institute Withdrawal Assessment for 
Alcohol – revised scale (CIWA-Ar scale; 24), or the Cushman score (32), the use of which is extremely 
widespread in France. When such monitoring conditions are not met, preventive BZD treatment 
should be implemented (EC).   
The use of long half-life BZDs is considered globally safe and is recommended (EC). Short half-life BZDs 
(such as oxazepam) have not demonstrated enhanced safety in this situation, and the clearance of 
oxazepam was found to be severely reduced among subjects with alcoholic liver disease (33). In the 
event of concerns about BZD use (e.g., chronic respiratory failure, decompensated liver cirrhosis with 
ascites, jaundice or prothrombin time <50%, obesity, advanced patient age) and the risk of withdrawal 
syndrome, residential detoxification is strongly recommended (EC). In such cases, BZDs can be 
administered according to a symptom-triggered protocol only in the event of patent signs of 
withdrawal and after the re-assessment of each dose (EC). In the event of severe withdrawal 
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symptoms or withdrawal events, treatment with BZDs should not be continued for more than four 
weeks, including the dose reduction phase (GRADE C). 
Thiamine (vitamin B1) is considered both a preventive and curative treatment for Wernicke’s 
encephalopathy, which can occur at any stage among individuals with an AUD, including during 
alcohol withdrawal (34). Because there is currently no clear evidence regarding how to use thiamine 
among alcohol-dependent individuals (34), the systematic initiation of a thiamine prescription is 
recommended, although the treatment dose and duration should be adapted to the subject’s 
underlying nutritional status (EC).  
 
3.4 How can relapse be prevented? 
If abstinence has been chosen as an objective, the aim of the treatment is to maintain abstinence, i.e., 
prevent relapse (see 3.1). When the treatment goal is abstinence, the therapeutic regimen usually 
includes an initial provision for alcohol detoxification. Relapse prevention corresponds to the 
therapeutic phase that follows alcohol withdrawal. In the past, relapse was defined as having the first 
drink after detoxification. More recently, relapse has been defined by the resumption of high-level use 
(greater than or equal to 5 units/day on a single occasion for males aged under 65 years; greater than 
or equal to 4 units/day for males over 65 years of age and for females)(35). It should be noted that 
these levels were defined by the US Food and Drug Administration, which defines a unit as 14 grams 
of alcohol, whereas a standard unit in France corresponds to 10 grams (36).  
The GRP recommendations regarding relapse prevention are listed in Table 5.  
- INSERT TABLE 5 HERE - 
In subjects with alcohol dependence, pharmacological treatments can be used to support abstinence. 
Medications for relapse prevention should be combined with adapted psychosocial support for 
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patients with alcohol dependence (GRADE A). Enhanced psychosocial support may increase motivation 
and thus compliance with medications, which, in turn, improves therapeutic efficacy (EC). 
Both acamprosate and naltrexone have been demonstrated to be efficacious for relapse prevention 
(37–39), and they display a globally good level of tolerability (37). Therefore, either medication can be 
used as a first-line treatment to support relapse prevention (GRADE A). Acamprosate has been found 
to be slightly more efficacious for maintaining abstinence, while naltrexone appears to be slightly 
more efficacious for reducing heavy drinking and craving (38). These features can help professionals 
decide which drug to prescribe, depending on the patient’s situation.  
Disulfiram has also demonstrated satisfactory efficacy for preventing relapse (40,41). It is worth 
mentioning that the drug’s specific mode of action implies that double-blind designs are not adequate 
(41). Moreover, disulfiram is associated with potentially harmful adverse drug reactions and safety 
issues (42). This drug requires close medical supervision and safety surveillance. It is thus 
recommended that disulfiram be proposed as second-line treatment for patients who are motivated 
to sustain abstinence and are adequately informed about the risk of the antabuse effect and 
adequately supervised (EC).  
In France, high-dose baclofen (HDB), i.e., up to 300 mg/d, has become a widespread off-label 
medication for alcohol dependence (10). Both general practitioners and addiction specialists can 
prescribe HDB, either for abstinence maintenance or drinking reduction (43,44). Although a recent 
clinical trial found that HDB had a significant effect on abstinence maintenance (45), the sample size of 
that trial was small, and the results of two clinical trials with larger samples are still being awaited 
(46,47). Moreover, HDB is known to induce frequent neuropsychiatric adverse drug reactions, such as 
sedation, dizziness, insomnia, and tinnitus (48–50). More rarely, seizures, manic symptoms, and 
baclofen withdrawal syndromes have been associated with HDB (51–53).    
In 2014, baclofen was officially authorized by the French Health Agency as a second-line prescription 
for preventing relapse among alcohol-dependent patients at doses up to 300 mg/d (54). This 
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authorization consists of a specific measure called a “temporary recommendation for use” (TRU) and 
is thus associated with a specific supervision procedure. The TRU will be applied until the results of the 
two aforementioned trials become available. In case of demonstrated efficacy, the TRU can be 
changed to an official labeling. Otherwise, the measure will be removed, and HDB will no longer 
benefit from any regulatory efforts to frame prescriptions and monitoring practices. The French GPRs 
have thus followed the TRU measure and have stated that HDB can be prescribed as a second-line 
treatment for abstinence maintenance at doses up to 300 mg/d only if the different criteria of the 
national regulatory measure are met.  
 
 3.5 How should treatment aimed at reducing drinking be conducted? 
In France, recommendations suggest that alcohol consumption be limited to below at‐risk use, i.e., 
fewer than 21 standard drinks (sd; 10 g of alcohol per sd) per week for males and fewer than 14 sd per 
week for females and fewer than 4 sd on each drinking occasion (EC). However, in certain 
circumstances, any use of alcohol is considered a risky behavior, e.g., during childhood or pregnancy, 
when driving an automobile or operating a machine, or in subjects with specific physical disorders or 
medical diseases. Thus, the ideal objective of drinking reduction programs should be personalized 
according to the patient’s needs.   
However, any reduction in alcohol use can have a significant impact on health. It has been 
demonstrated an exponential relationship between alcohol use and the risk of death (55), and 
reductions in consumption have a greater impact when the level of initial consumption is higher. For 
example, a reduction of 36 grams of alcohol per day was calculated as reducing the risk of death by 
three times more in a drinker who consumes 96 g/day than in a drinker who consumes 60 g/day (56). 
Therefore, several recommendations have been issued on how to conduct a drinking reduction 
treatment (see Table 6).  
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- INSERT TABLE 6 HERE - 
It is recommended that consumption below the at‐risk levels be targeted insofar as possible, although 
any lasting reduction in consumption should be considered a positive result and a possible initial step 
towards a greater reduction (EC). 
The reduction of alcohol consumption can be directly proposed to patients with mild dependence or 
to patients with a more severe disorder who do not wish or are not yet able to attempt abstinence 
(EC).  
Until early 2010, psychosocial interventions were the only therapeutic strategies available for alcohol 
treatment. Since then, medicinal strategies have become available. The psychosocial interventions 
recommended for reducing alcohol use among patients with alcohol dependence are motivational 
interventions and cognitive behavioral programs, notably behavioral self‐control training (57). The 
most important therapeutic element appears to be daily self‐monitoring of consumption (57), which 
should be routinely used across drinking reduction programs (GRADE A). 
Pharmacological treatments that support drinking reduction have only been evaluated in individuals 
with alcohol dependence and are thus recommended only for that population (EC). Nalmefene is the 
first medicinal product to demonstrate efficacy for reducing alcohol consumption in subjects with 
alcohol dependence (58), and it is also the first drug to receive regulatory labeling in France for the 
indication of reducing drinking in alcohol-dependent individuals. Although naltrexone is normally 
indicated for the prevention of relapse after withdrawal (see 3.4), some data indicate that it may have 
efficacy for reducing alcohol use (59). As indicated in part 3.4, the prescription of HBD to reduce 
alcohol use among alcohol‐dependent patients has been authorized by the TRU measure since March 
2014 at doses up to 300 mg/d until further data are available.  
Consequently, nalmefene is recommended as the first-line medication for reducing alcohol 
consumption in subjects with alcohol dependence (GRADE A). The use of HDB to treat alcohol use 
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among alcohol‐dependent patients should be considered a second-line option, and its prescription 
should strictly follow the criteria of the TRU measure (EC).  
3.6 How treatment should be managed in specific populations: pregnant women, 
adolescents, the elderly, and individuals with somatic or psychiatric comorbidities or 
multiple-substance use 
 
Table 7 lists the main recommendations for managing treatment in specific populations.  
Given the lack of any current international consensus on alcohol toxicity thresholds for embryos or 
fetuses, abstinence throughout pregnancy is recommended for pregnant women, including pregnant 
women with alcohol dependence (EC). Pregnancy in a woman who misuses alcohol is a medical 
priority and requires the cessation of all alcohol use as soon as possible, regardless of the term during 
which the intervention takes place (EC). The patient must be managed by a multidisciplinary 
community/hospital team (EC). If medically assisted withdrawal is necessary during pregnancy, short-
term use of BZDs is currently considered safe for the dyad (60,61) and is therefore recommended 
(GRADE B).  
No medical treatments designed to help maintain abstinence or achieve a reduction in alcohol use 
have been properly evaluated in pregnant or breastfeeding women with alcohol dependence. It is 
therefore recommended that no treatments other than those for alcohol withdrawal be initiated in 
pregnant or breastfeeding women (EC). In the event that a pregnancy occurs in a patient who is 
obviously stabilized by pharmacological treatment, the continuation of treatment should be 
considered on a case‐by‐case basis by weighing the benefit/risk ratio (EC). Treatment with disulfiram is 
an exception to this recommendation; it is preferable to discontinue disulfiram treatment in particular 
because the risks of the antabuse effect on the fetus are unknown (EC). In other cases, the decision 
must be pragmatic and reached after a multidisciplinary consultation involving at least the patient's 
own doctor, the addiction specialist, the obstetrician and the regional pharmacovigilance center (EC). 
 
- INSERT TABLE 7 HERE - 
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In adolescence, alcohol dependence is commonly associated with severe psychiatric disorders and 
family problems (62). Therefore, any adolescent under the age of 16 years with alcohol dependence 
should undergo a pediatric psychiatric assessment (GRADE C). Because the overall prognosis is less 
favorable in such situations (63), abstinence is often the preferred goal (GRADE C). However, given 
that it is sometimes difficult to get these young patients to agree to abstain, it may be necessary to 
establish a goal of drinking reduction as part of a harm-reduction strategy (EC). Given the absence of 
specific data regarding the use of medication for alcohol dependence in adolescents, first‐line 
treatments to help maintain abstinence or reduce drinking do not have marketing authorization in 
France or elsewhere for subjects under the age of 18 years. Off-label use of medication is 
recommended on a case-by-case basis and only for severe misuse after the repeated failure of 
psychosocial measures alone (EC).  
 
In elderly patients with alcohol dependence, especially those who vulnerable because of physical 
disability, heavy medication use, or cognitive impairment, it is preferable to conduct the detoxification 
process in a hospital setting to control or more easily prevent serious complications, i.e., delirium 
tremens, convulsions, falls, and intracerebral hematomas (EC). In addition, it is essential to ensure 
good hydration in these subjects, who frequently have cardiovascular problems and a precarious 
fluid‐electrolyte balance (EC). The onset of withdrawal syndrome may be delayed in elderly patients 
compared to younger ones. Given the pharmacokinetic and pharmacodynamics modifications 
observed in this population, particular caution is required when prescribing BZDs (EC). 
BZDs remain the treatment of choice for the elderly; however, in contrast with the recommendations 
for younger adult populations, short half-life BZDs reduce the risk of accumulation (64,65) and the 
resulting adverse events, such as sedation and falls, in the elderly (66). Therefore, short half-life BZDs 
are preferred for elderly patients (GRADE B). Initial doses must be reduced by 30 to 50% (EC).  
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Medicinal treatment to reduce alcohol use or prevent relapse among the elderly is no different than 
the recommendations for younger patients. Social and environmental management that aims to 
combat isolation is particularly important (GRADE B) because it is a major cause of alcohol misuse in 
the elderly (67). For patients living at home, meal delivery, home‐help services and community nurse 
visits can support abstinence maintenance (EC). Such visits are also a way of alerting medical and 
social services in the event of difficulties. For patients living in an institution, improving their living 
environment, engaging them in support groups and breaking their solitude are also invaluable (EC). 
 
Patients with both alcohol dependence and alcohol-related physical complications should be offered 
coordinated care that includes an addiction specialist, the concerned specialist(s) and the patient’s 
general practitioner (EC). Given the absence of clear data regarding the existence of a toxicity 
threshold in patients with liver cirrhosis, pancreatitis, cognitive disorders, ataxia or peripheral 
neuropathy, alcoholic cardiomyopathy, alcohol‐related cancer or other chronic somatic complications 
related to alcohol, abstinence is recommended in these situations (EC). If the patient is unwilling to 
stop drinking, intermediate objectives to reduce his/her alcohol use may be established with the aim 
of limiting damage, but the final goal remains total abstinence (EC). 
 
In patients with liver cirrhosis, baclofen, at a dose of 30 mg/d, has demonstrated encouraging results 
in cirrhosis patients (68). To date, higher dosages have not been assessed in this population, and 
severe liver failure is a contraindication for the use of baclofen according to the TRU. When alcohol 
detoxification is required in subjects with alcohol liver disease, oxazepam should not be considered 
safer in this population (see part 3.3). In the case of decompensated liver cirrhosis with ascites, 
jaundice or prothrombin time <50%, residential detoxification is strongly recommended (EC). In similar 
cases, the use of naltrexone for abstinence maintenance is contraindicated. In contrast, acamprosate 
has a good global safety profile, and the absence of liver metabolism and of pharmacokinetic 
18 
 
interactions with alcohol could represent an advantage in the treatment of alcohol dependent 
patients affected by end-stage alcoholic liver disease; however, no trials with repeated administrations 
of acamprosate in these patients have been performed. In cases of less-severe alcoholic liver diseases, 
including compensated cirrhosis, naltrexone treatment is possible as long as monthly laboratory tests 
(prothrombin time, transaminases) are performed. 
 
Some patients with alcoholic liver cirrhosis may need a liver transplantation (69), after which some of 
these subjects do appear able to resume stable low‐risk alcohol use (70); however, in light of the 
current absence of sufficient ongoing data and given the significant impact of resumed misuse on the 
transplanted organ (69, 71), continued abstinence should be maintained insofar as possible (EC).  
 
The cognitive disorders induced by alcohol are often reversible after detoxification, but their 
persistence has a negative impact on treatment compliance and living conditions (72). Consequently, 
if an alcohol‐induced cognitive disorder is suspected or diagnosed, particularly in conjunction with 
alcoholic liver disease or nutritional deficiencies, the management of the detoxification and post-
detoxification period in a residential setting is preferable to outpatient management for obtaining 
protracted abstinence (EC). 
 
Depressive symptoms are often observed in patients presenting non‐stabilized alcohol misuse. In the 
majority of cases, these symptoms quickly disappear after detoxification or a significant reduction in 
alcohol use (73,74). A diagnosis of major depressive episode and the introduction of an antidepressant 
should only be considered after the alcohol misuse is in remission, i.e., abstinence or low-risk use for 2 
to 4 weeks (GRADE B). At the present time, no particular antidepressant treatment has shown 
superiority over the others in patients with alcohol dependence (75); thus, no particular drug should 
thus be globally preferred (GRADE A). Severe symptoms of depression may indicate a need for 
medically managed detoxification in a residential setting (EC). Alcohol misuse frequently causes 
symptoms of anxiety, which are sometimes severe. In this case, too, symptoms disappear or often 
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improve after detoxification or a marked reduction in alcohol use (74). As with depression symptoms, 
long-term pharmacological treatments of the anxiety should only be considered after a psychiatric 
reassessment of the patient in a remission state, i.e., after the patient has abstained or been drinking 
at a low‐risk level for 2 to 4 weeks (GRADE B). 
The presence of concomitant addictive disorders always requires a global management program that 
incorporates all substances, including tobacco. In the event of medically managed detoxification, 
quitting smoking at the same time reduces risk of a subsequent alcohol relapse (76). A smoking 
cessation approach is therefore recommended, and pharmacological assistance should be 
systematically offered to smokers when they are giving up alcohol in either a hospital or an outpatient 
setting (GRADE B). 
 
4. DISCUSSION 
The aim of the present article was to synthesize the portions of the 2015 French GPRs that pertain to 
the pharmacotherapy of alcohol dependence. As indicated above, a nation’s guidelines are not a mere 
literature review of the evidence; they should also integrate the nation’s care system and medical 
habits. They may also propose recommendations in areas where no evidence is currently available. 
Consequently, the guidelines issued in different countries can vary on several points, despite a basis in 
the same literature. Thus, a comparison of the French GPRs with other national guidelines is 
warranted. For instance, a very illustrative example of transnational differences is the determination 
of low-risk thresholds, which are highly variable among countries (36).  
Regarding pharmacotherapy, France has developed some prescribing particularities over time. 
Diazepam has been by far the most widely used BZD for alcohol detoxification. In many other 
countries, the use of chlordiazepoxide is also very common. For example, both diazepam and 
chlordiazepoxide are recommended as first-line detoxification treatments in the National Institute for 
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Clinical Excellency (NICE) guidelines, i.e., the English recommendations (77). In some other countries, 
such as Australia, chlordiazepoxide is not labeled, and diazepam is thus the only first-line 
recommendation (78). In France, chlordiazepoxide has been labeled for anxiety but not for alcohol 
detoxification, and it is not routinely used for this indication in clinical practice. For this reason, only 
diazepam has been recommended in the GPRs. It is noteworthy that BZDs have not shown a clear 
superiority to some anticonvulsants (i.e., carbamazepine) in the management of alcohol withdrawal 
(28). The recommendation of BZDs as first-line pharmacotherapy is therefore based on widespread 
consensus rather than on clear evidence. Moreover, the choice not to recommend short half-life BZDs 
for the management of detoxification in patients with liver disease can appear confusing, because this 
use is frequent in practice and was mentioned by previous expert statements (79, 80). However, these 
previous statements were completely empirical, and the scientific comparisons between using short 
or long half-life BZDs for alcohol detoxification actually appear both scarce and contradictory (33, 81). 
Consequently, after a long debate, the working group decided not to clearly recommend short half-life 
BZDs in this case. It is also warranted to mention sodium oxybate, which has been found efficacious 
notably for the prevention of AWS (82), and is labeled in Italy and Austria for both preventing AWS and 
maintenance abstinence. Nevertheless, sodium oxybate is currently not labeled in France and was 
thus not directly discussed in the GPRs.  
For the indication of abstinence maintenance, disulfiram is recommended in the French GPRs as a 
second-line treatment for patients who have experienced a previous failure of naltrexone or 
acamprosate. This is essentially because of concerns about the safety of the drug. The same 
recommendation can also be found in the NICE guidelines (77) but not in the Australian guidelines, 
which allow the first-line prescription of disulfiram with certain precautions (78). 
Undoubtedly, the most recent French prescribing particularity has been the off-label use of HDB. This 
practice initially derived from a single-case patient-physician account (83) whose story was widely 
disbursed in the media (10). In France, HBD is used equally for drinking reduction and abstinence 
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maintenance (44). This prescribing practice has also been noted in French-speaking border countries, 
such as Belgium and Switzerland (84,85). Moreover, the use of HDB has also been reported in non-
French-speaking countries, such as Germany, where the first positive results were found for HDB in 
abstinence maintenance (45). Nevertheless, France is currently the only country where HDB 
prescriptions have been regulated by the national drug agency. HDB is mentioned in the Australian 
guidelines, and the last-resort utilization of HDB has been reported by Australian researchers in case 
series (86). In Italy, baclofen has a long history of use among some teams, but essentially at low doses 
(87). In contrast, baclofen does not seem to be used for alcohol dependence in the UK, and the NICE 
does not even mention the drug. If the recent large-sample clinical trials that have been conducted in 
France provide significant results (46,47), European labeling might be bestowed upon HDB. This could 
homogenize the HDB prescription practices, which are currently very heterogeneous among European 
countries.  
It is worth noting that despite its off-label status, baclofen was one of the first medications to be used 
for drinking reduction in France before the commercial availability of nalmefene. In fact, the 
publication of the new French GPRs was warranted in part because of the emergence of this new 
treatment concept. Studies of patient preferences have highlighted that drinking reduction should be 
offered as an additional treatment option for alcohol-dependent subjects (88), and the recent clinical 
trials of nalmefene have provided further evidence that a pharmacological treatment could support 
drinking reduction in subjects with alcohol dependence who drink heavily (58, 89–92). However, 
several aspects of the pharmacotherapy of drinking reduction and controlled drinking remain to be 
clarified. In practice, switches in drinking patterns can be observed in all directions. Only a few of 
these changes have been investigated in clinical trials; thus, many situations have been poorly 
codified. For example, it is unclear whether patients with alcohol dependence who decide to attempt 
to resume low-risk drinking after a period of abstinence can benefit from pharmacological support. No 
drug is currently indicated in such situations, and there is currently no empirical evidence that such an 
approach is sensible for patients.  
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Despite the consideration of the French national care system and clinical practices in the drafting of 
the GPRs, external (non-French) participation was also important for the transparency and quality of 
the GPRs. This was the role served by the EUFAS members who were on the steering committee or 
who participate in the document’s review process. This involvement should be viewed as one of the 
first benefits of the EUFAS’ mission, which includes the promotion of cross-European interaction with 
regard to clinical practices (93). The next step could consist of elaborating homogenous European 
GPRs, but such a project could also come up against very heterogeneous local practices and 
regulations.     
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TYPE OF STUDIES ON WHICH THE RECOMMENDATION IS BASED 
 
GRADE OF 
RECOMMENDATION 
 
 
 
RECOMMENDATION BASED ON ESTABLISHED SCIENTIFIC EVIDENCE 
 
i.e., based on studies with a high level of evidence (LEVEL OF EVIDENCE 1): 
- randomised comparative trials with high power and no major biases 
- meta-analysis of randomised comparative trials 
- decision analysis based on properly conducted studies 
 
A 
 
 
RECOMMENDATION BASED ON SCIENTIFIC ASSUMPTION 
 
i.e., based on studies with an intermediate level of evidence (LEVEL OF EVIDENCE 2): 
- randomized comparative trials with low power 
- properly conducted non-randomized comparative studies 
- cohort studies 
 
B 
 
 
RECOMMENDATION BASED ON WEAK LEVEL OF EVIDENCE 
 
i.e., based on studies with an low level of evidence  
- LEVEL OF EVIDENCE 3: case-control study 
- LEVEL OF EVIDENCE 4: retrospective studies, case series, or comparative studies with major biais 
 
 
 
 
C 
 
 
 
RECOMMENDATION BASED ON EXPERT CONSENSUS 
 
If no studies are available, the recommendations are based on a consensus between working group experts,  
after consulting the review group. 
 
The absence of classification does not mean that the recommendations are not relevant and useful.  
However, this should prompt additional studies. 
  
 
 
 
 
EC 
 
TABLE 1. Recommendation grading according to the Haute Autorité de Santé, i.e., the French High Autorithy for Health [X]  
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   #         RECOMMENDATION GRADE 
 
6.1 
 
Therapeutic intervention aims for a change in alcohol use: abstinence or moderation EC 
 
6.2 
 
The goal of treatment should be set with the service user B 
 
6.3 
 
 
Abstinence is the appropriate goal for severe alcohol dependence, and/or dependence with significant psychiatric or physical comorbidity (e.g., 
depression or alcohol-related liver disease). If the service user is unwilling to reach a goal of abstinence, a supported harm reduction program of 
care should be considered 
 
 
 
EC 
 
 
 
6.4 
 
 
For mild dependence without significant comorbidities and with adequate social support, the treatment objective can be a moderate level of 
drinking unless the service user prefers abstinence or there are other reasons for advising abstinence 
  
 
 
EC 
 
 
6.5 
 
 
The goal for moderation should ideally aim not to exceed 21 standard units of alcohol (i.e., 210 g of alcohol) per week for males and 14 standard 
units of alcohol (i.e., 140 g of alcohol) per week for females 
 
However, any significant reduction in average alcohol use, as in the proportion of days with excessive use, is liable to provide substantial benefit to 
the individual  
  
 
EC 
 
 
A 
 
 
TABLE 2 Recommendations issued on the objectives of therapeutic intervention (QUESTION 6 of the RCPs)  
Each recommendation was graded from A to C using the methodological tool published by the Haute Autorité de Santé (HAS), 
i.e., the French High Autorithy for Health [X], according to the level of evidence of the studies on which the recommendation was 
based (see Table 1). EC= „expert consensus‟, i.e., recommendations issued on consensual expert opinion, when no study was 
available; RCPs= „recommendations for clinical practice‟. 
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   #        RECOMMENDATION 
 
GRADE 
 
 
7.12 
 
 
Benzodiazepines (BZDs) are the first-line medication for alcohol withdrawal syndrome  
 
Using benzodiazepines with long half-life should be preferred 
 
 
A 
 
EC 
 
7.13 
 
 
The indication for and tailoring of  BZD treatment  should be guided by regular and rigorous clinical surveillance, which may be supported by 
withdrawal symptom evaluation scales (CIWA-Ar scale or Cushman score) 
 
B 
7.15 
 
 
In the event of contraindication to BZDs (e.g., chronic respiratory failure, decompensated liver cirrhosis with ascites, jaundice or Prothrombin time 
<50%, obesity, elderly patients), and a risk of withdrawal syndrome, residential detox is strongly recommended 
 
BZDs should be administered according to an symptom-triggered protocol, only  in the event of patent signs of  withdrawal and after re-
assessment of each dose 
 
BZDs with a short half-life (such as oxazepam) have not demonstrated better safety in this situation, and their half-life may be prolonged in the 
event of liver failure 
 
 
 
EC 
 
EC 
 
 
B 
 
7.16 
 
 
Symptom-adjusted prescription of BZDs applies more to residential detoxification. Residential detox is appropriate for patients with difficulty in 
communicating, history of seizures, unstable psychiatric comorbidity or other associated addiction 
  
B 
 
7.17 
 
 
BZDs are only justified beyond a one-week period in the case of persistent withdrawal! symptoms, withdrawal events or associated BZD 
dependence 
  
 
 
B 
 
 
7.18 
 
 
In the event of severe withdrawal symptoms or withdrawal events, treatment with BZDs should not be continued for more than four weeks, 
including the dose reduction phase 
C 
7.19 
 
Routine prescription of thiamine (vitamin B1) should be adapted to nutritional status 
 
EC 
 
11.1 
 
Residential detox is indicated in the following cases: delirium (mental confusion and/or hallucinations) or epileptic seizures at the time of 
evaluation; history of delirium or epileptic seizures; high-dose multiple drug use, notably concomitant BZD dependence 
 
Residential treatment should also be envisaged on a case-by-case basis under certain circumstances: extent of withdrawal syndrome, failure of 
repeated outpatient detoxification, severe or unstable comorbidity, age-related frailty, pressing demand from family, limited social support, 
precarious social situation, pregnancy 
 
 
EC 
 
11.2 Outpatient detoxification should be preferred apart from the indications for residential detoxification 
 
EC 
 
11.3 
 
In the majority of cases, detoxification does not require pharmacological treatment, provided thorough and repeated clinical evaluations take place 
before and during the detoxification process 
 
 
B 
 
 
36 
 
When such monitoring conditions are not met, preventive BZD treatment should be implemented  
 
EC 
 
11.4 
 
Unless disproportionate depressive symptoms are observed, the initiation of an antidepressant treatment is not indicated during the detox 
procedure 
 
 
EC 
 
 
 
TABLE 3 Recommendations issued on the overall management of alcohol detoxification (i.e., Questions 7 and 11 of the RCPs)  
Each recommendation was graded from A to C using the methodological tool published by the Haute Autorité de Santé (HAS), i.e., the French High 
Autorithy for Health [X], according to the level of evidence of the studies on which the recommendation was based (see Table 1).  
EC= ‘expert consensus’, i.e., recommendations issued on consensual expert opinion, when no study was available; RCPs= ‘recommendations for clinical 
practice’.  
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   #        RECOMMENDATION 
 
GRADE 
 
 
12.4 
 
 
Medications for relapse prevention should be automatically associated with adapted psychosocial support in patients with alcohol-dependence 
 
A 
 
12.5 
 
 
Increased compliance with medications improves therapeutic efficacy 
 
EC 
 
12.6 
 
 
Acamprosate or naltrexone are the first-line treatment for supporting relapse prevention 
 
 
A 
 
 
 
12.7 
 
Disulfiram can be proposed as second-line treatment in patients motivated to sustain abstinence, correctly informed of the risk of the antabuse 
effect, and adequately supervised 
  
 
 
EC 
 
 
 
12.8 
 
The second-line prescription of baclofen for preventing relapse among alcohol-dependent patients has been authorized by a “temporary 
recommendation for use” (TRU) up to the dose of 300 mg/d, and requires the online reporting of patients‟ follow-up on the TRU portal. Doses 
should be increased and decreased slowly according to efficacy and tolerability 
  
 
 
 
EC 
 
TABLE 4 Recommendations issued on the management of relapse prevention (QUESTIONS 7 & 11 of the RCP document)  
Each recommendation was graded from A to C using the methodological tool published by the Haute Autorité de Santé (HAS), i.e., the 
French High Autorithy for Health [X], according to the level of evidence of the studies on which the recommendation was based (see Table 
1). EC= ‘expert consensus’, i.e., recommendations issued on consensual expert opinion, when no study was available; RCP= 
recommendations for clinical practice. 
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   #        RECOMMENDATION 
 
GRADE 
 
 
10.1 
 
 
Reducing consumption can be directly proposed to patients with mild dependence, or to patients with a more severe disorder who do not wish or 
are not yet able to attempt abstinence 
 
EC 
 
10.2 
 
 
It is recommended that consumption below the at-risk levels be targeted insofar as possible, although any lasting reduction in consumption should 
be accepted as a positive result, and may be an initial step towards a greater reduction 
 
EC 
 
10.3 
 
Self‐assessment of daily alcohol consumptions should be used in psychosocial support for drinking reduction 
 
A 
 
 
10.4 
 
Medications for reducing alcohol consumption are only indicated in dependent individuals 
  
 
EC 
 
10.5 
 
 
Nalmefene is indicated as a first-line treatment for reducing alcohol consumption in dependent individuals  
 
A 
 
 
 
10.6 
 
The second-line prescription of baclofen for reducing alcohol use among alcohol-dependent patients has been authorized by a “temporary 
recommendation for use” (TRU) up to the dose of 300 mg/d, and requires the online reporting of patients‟ follow-up on the TRU portal 
  
 
 
EC 
 
TABLE 5. Recommendations issued on the conduction of a drinking reduction strategy (QUESTIONS 7 &10)  
Each recommendation was graded from A to C using the methodological tool published by the Haute Autorité de Santé (HAS), 
i.e., the French High Autorithy for Health [X], according to the level of evidence of the studies on which the recommendation was 
based (see Table 1). EC= „expert consensus‟, i.e., recommendations issued on consensual expert opinion, when no study was 
available 
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   #        RECOMMENDATION 
 
GRADE 
 
16.2 
 
Abstinence throughout pregnancy is recommended for any pregnant women 
 
EC 
 
16.4 
 
If medically‐assisted withdrawal is necessary during pregnancy, using BZDs is recommended  B 
 
16.5a 
 
No treatments other than those for alcohol withdrawal should be initiated in pregnant or breastfeeding women 
 
EC 
 
 
16.5b 
 
In the event of a pregnancy occurring in a patient obviously stabilized by a medication for supporting abstinence, the continuation of the drug 
should be considered on a case‐by‐case basis, weighing up the benefit/risk ratio. 
  
 
 
EC 
 
16.5c 
 
 
Disulfiram is an exception, and it should be always stopped during pregnancy, to the unknown risks on the fetus of the antabuse effect  
 
EC 
 
 
 
16.7a 
 
Any adolescent with alcohol dependence under the age of 16 should undergo a pediatric psychiatric assessment  C 
 
16.7b 
 
In the case of alcohol dependence occurring under the age of 16, the objective of abstinence should be preferred   EC 
 
16.7c 
 
 
First‐line treatments to help maintain abstinence or reduce drinking are off-label, and should thus be considered on a case-by-case basis, after 
repeated failure of psychosocial measures alone. 
 
 
 
EC 
 
 
 
16.8a 
 
In elderly patients with alcohol-dependence, it is preferable to conduct the detoxification process in a hospital setting  EC 
 
16.8b 
 
Short half-life benzodiazepines should be preferred for detoxification in elderly patients  B 
16.8c 
 
Initial doses of benzodiazepines should be reduced by 30 to 50% in elderly patients 
 
 
 
EC 
 
 
16.8d 
 
Psychosocial support should be particularly emphasized in elderly patients with alcohol dependence  B 
 
 
16.10 
 
 
In patients with chronic alcohol-related physical disorders, a goal of abstinence is recommended 
 
EC 
 
16.11 
 
 
Antidepressants or anxiolytic medication should be introduced only after reassessment of the psychiatric state, after 2-4 weeks of alcohol 
abstinence or low-risk use  
B 
 
16.12 
 
It is recommended that a smoking cessation approach be encouraged and that pharmacological assistance be systematically 
offered to smokers when they are giving up alcohol, in either a hospital or an outpatient setting (GRADE B) 
 
 
B 
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TABLE 6 Recommendations issued on the management of treatment for alcohol dependence in specific population, i.e., pregnant 
women, children and adolescents, elderly subjects, comorbid alcohol-related physical conditions, comorbid psychiatric 
and substance use disorders (QUESTIONS 16 of the RCPs)  
Each recommendation was graded from A to C using the methodological tool published by the Haute Autorité de Santé (HAS), 
i.e., the French High Autorithy for Health [X], according to the level of evidence of the studies on which the recommendation was 
based (see Table 1). EC= „expert consensus‟, i.e., recommendations issued on consensual expert opinion, when no study was 
available; RCPs= recommendations for clinical practice.  
 
 
 
